Table 1.
Baseline metabolicsyndrome characteristics of subjects
| Clinical Measurement | Placebo (n=14) | Resveratrol (n=14) | p | ||
|---|---|---|---|---|---|
| Mean±SD | CI 95% | Mean±SD | CI 95% | ||
| FBG (mg/dl) | 104±22 | 92.–117 | 98±12 | 91–105 | 0.322 |
| HDL (mg/dl) | 42±9 | 37–47 | 40±7 | 36–44 | 0.672 |
| TG (mg/dl) | 146±6 | 114–179 | 125±75 | 82–168 | 0.409 |
| SBP (mmHg) | 119±9 | 115–124 | 118±6 | 115–121 | 0.717 |
| DBP (mmHg) | 77±6 | 74–81 | 78±2 | 77–80 | 0.457 |
| Waist circ (cm) | 116±8 | 111–120 | 117±11 | 111–123 | 0.813 |
Comparison of the baseline metabolic syndrome characteristics of the total group of resveratrol and placebo treated subjects. mg/dl: Milligrams per deciliter, FBG: Fasting blood glucose, HDL: High density lipids, TG: Triglycerides, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, mmHg: Millimeters of mercury, cm: Centimeter, waist circ: Waist circumference, SD: Standard deviation, CI: Confidence interval.